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Abstract
Liver transplant is a treatment for familial amyloid
polyneuropathy. Few cases of ABO-incompatible
living-donor liver transplant for familial amyloid
polyneuropathy exist. The outcome of an ABO-
incompatible living-donor liver transplant has
improved recently, using local infusion therapy and
rituximab prophylaxis. Here, we describe a successful
ABO-incompatible living-donor liver transplant in a
patient with familial amyloid polyneuropathy in
whom disease progression ceased at 2 years’ follow-
up. Additionally, no evidence of acute or chronic
rejection, or adverse events of the immuno-
suppressive therapy, was seen. As a postoperative
complication, fatty changes in the grafted liver
because of malnutrition or adverse events of
corticosteroids were confirmed by a liver biopsy
taken early after transplant. The main cause of
malnutrition was considered to be gastrointestinal
dysfunction caused by familial amyloid poly-
neuropathy. Therefore, before deterioration of
digestive function, liver transplants should be
considered for familial amyloid polyneuropathy. This
case suggests that an ABO-incompatible living-donor
liver transplant may provide greater opportunities
for familial amyloid polyneuropathy patients.
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Introduction
Familial amyloid polyneuropathy (FAP) is an
inherited form of systemic amyloidosis characterized
by peripheral somatic and autonomic neuropathy
associated with various involvement of visceral
organs. Liver transplant is the treatment for FAP and
is associated with favorable outcomes.1 However,
FAP is rare, and only 2 cases have been reported of
ABO-incompatible (ABO-I) living-donor liver
transplant (LDLT) for FAP patients.2,3 Therefore,
clinical features and treatment of FAP with ABO-I
LDLT have not been studied in detail. Here, we
describe an FAP patient who underwent an ABO-I
LDLT. 
Case Report
The patient was a 35-year-old man, with a body mass
index of 22.2 kg/m2. He was impotent at 24 years of
age, owing to erectile dysfunction. He had diarrhea
and hypohidrosis at 32 years of age. Orthostatic
hypotension was noted at 33 years of age. He had
frequent diarrhea, anorexia, languor, fatigue, and
paresthesia of the planta pedis from the age of 34
years onward. Because amyloid deposits were
detected in the skin and large intestinal mucosal
biopsy specimens by Congo red staining, his disease
was diagnosed as FAP at 34 years of age. He
underwent vitreous surgery to treat a vitreous
opacity in his right eye at 30 years of age and in his
left eye at 33 years of age. His father was diagnosed
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as having FAP and died at 43 years of age.
Additionally, his grandmother was diagnosed as
having FAP. 
He was referred to our Department of
Gastroenterologic Surgery at Kanazawa University
for LDLT. The donor was his healthy mother. The
recipient’s blood type was A (+), which differed from
the donor type of B (+). Although ABO-I LDLT was
avoided, there was no candidate donor. Before the
ABO-I LDLT, he underwent preoperative plasma
exchange twice with fresh frozen plasma and was
administered rituximab (375 mg/m2) twice. These
treatments effectively reduced his serum anti-B
antibody level from 1:16 to 1:1 immediately before
transplant. We performed an ABO-I LDLT using a
right lobe graft without the middle hepatic vein 
(645 g), with splenectomy and intraportal
catheterization. The graft recipient body weight ratio
was 0.82 and comprised 49% of his standard liver
volume. Immunosuppressants consisted of tacro-
limus, mycophenolate mofetil, and a corticosteroid.
Prostaglandin E1, methylprednisolone, and heparin
were administered via the portal vein for 2 weeks.
The target trough level of tacrolimus was 10 to 15
ng/mL for the first 2 weeks and was decreased
gradually afterwards.
A slight increase in biliary tract enzyme levels
was observed approximately 2 weeks after the LDLT.
A liver biopsy was performed on postoperative day
23 for pathological investigation. Ten percent fatty
changes in the graft were confirmed by
histopathology. Fatty changes in the liver worsened
on postoperative day 42, and a liver biopsy specimen
revealed 70% to 80% macrovesicular steatosis 
(Figure 1). Color Doppler ultrasonography showed
no abnormalities. Computed tomography (CT) scans
revealed severe fatty changes in the grafted liver
(Figure 2A) but neither vascular stenosis nor
thrombosis. 99m-Tc galactosyl human serum
albumin liver dynamic single-photon emission
computed tomography did not reveal any
deterioration in hepatic function. We suspected that
either malnutrition resulting from the digestive
disorder or adverse events of corticosteroid
administration were associated with fatty liver. The
patient had continued diarrhea and reduced dietary
intake after the LDLT. We thought that
mycophenolate mofetil administration was the
precipitating factor for diarrhea, and reduced the
dosage. We also tapered the dosage of corticosteroids.
Computed tomography scans revealed marked
improvement in fatty changes in the liver on
postoperative day 144 (Figure 2B). As with other
complications, cytomegalovirus antigen-positive status
or cholangitis were often observed and treated with
medication. No evidence of acute and chronic
rejection or adverse events of the immuno-
suppressive therapy were observed at 2 years’
follow-up. No abnormalities were reported in cardiac
or renal function; however, treatment of diarrhea and
orthostatic hypotension continued.
Discussion
The outcome of an ABO-I LDLT has improved
recently by using local infusion therapy and
rituximab prophylaxis.4 The number of deceased
donors is limited in Japan, and living relatives are the
main source of donors. The indications for liver
transplant in our department have been extended to
ABO-I. According to the Japanese Liver Trans-
plantation Society, 3872 adult patients until 2010
underwent an LDLT. Three hundred forty-seven
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Figure 1. Liver Biopsy Specimen Revealed 70% to 80% Macrovesicular
Steatosis
Figure 2. A Plain Computed Tomography Scan of the Grafted Liver Showed
Severe Fatty Changes
(A) Postoperative day 42 and (B) marked improvement in fatty changes in the
liver on postoperative day 144.
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(8.96%) had undergone an ABO-I LDLT; 72 of which
(1.85%) had FAP.5 
Two previous cases of an ABO-I LDLT for FAP
have been reported.2,3 Case No. 1 was a patient with
late-onset FAP who underwent an auxiliary partial
orthotopic liver transplant from an ABO-I living
related donor showing marked clinical improvement.2
Case No. 2 also had a favorable outcome.3 We
described a successful ABO-I LDLT for an FAP patient
in whom progression of FAP had been stopped at 2
years’ follow-up. These cases suggest that an ABO-I
LDLT provides greater opportunities to FAP patients.
Fatty changes in the grafted liver were confirmed
pathologically in this case. Previous studies
described an 18% incidence of de novo nonalcoholic
fatty liver disease and 9% for de novo nonalcoholic
steatohepatitis after liver transplant after an average
28 months’ follow-up.6 The use of tacrolimus,
posttransplant obesity, diabetes mellitus,
hypertension, hyperlipidemia, steatosis in the donor
liver, and alcoholic liver disease as primary
indications for liver transplant are predictors after a
liver transplant of nonalcoholic fatty liver disease.7
Early fatty changes in the liver within 1 month of an
LDLT because of vascular complications (eg,
thrombosis of the portal system) also have been
reported.8 Our case developed fatty liver in the early
posttransplant period; however, neither vascular
complications nor the predictors of nonalcoholic fatty
liver disease described previously were observed. We
could not identify a specific cause for fatty changes in
the liver. However, the effectiveness of relieving the
diarrhea and reducing the dosage of corticosteroids
suggest that a combination of malnutrition from the
gastrointestinal dysfunction because of FAP and
drug adverse events may have contributed to
development of fatty liver. Malnutrition has been
shown to lead to fatty liver because of an
overproduction of triglyceride deposits in the liver
after an increase in free fatty acid beyond the ability
of liver lipoprotein metabolism.8 Such a low
nutritional status may have occurred in our case
because of continued diarrhea and reduced intake
food. As suggested previously,9 before deterioration
of digestive function, liver transplant should be
considered. 
Long-term survival after liver transplant in FAP
patients is good10; however, there are no studies of
FAP patients alone after an ABO-I LT or an LDLT.
The accumulation of more cases and further 
follow-up are warranted to examine whether
survival rates and clinical symptoms of FAP patients
after an ABO-I liver transplant are similar to those of
an ABO-identical/compatible liver transplant.
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